natgillin/translations-raw huggingface dataset:
The most frequently reported adverse reactions with Trydonis were oral candidiasis (which occurred in 0.8% of the exposed subjects), which is normally associated with inhaled corticosteroids; muscle spasms (0.4%), which can be attributed to the long-acting beta2-agonist component; dry mouth (0.4%), which is a typical anticholinergic effect.
izpostavljenih oseb), ki je normalno povezana z inhalacijskimi kortikosteroidi; mišični spazmi (0,4 %), ki se lahko pripišejo sestavini dolgodelujočega agonista adrenergičnih receptorjev beta2; suha usta (0,4 %), kar je običajni antiholinergični učinek.
Study TRINITY compared Trydonis with tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily; in addition, effects were compared with an extemporary triple combination made of a fixed combination of beclometasone dipropionate and formoterol 100/6 micrograms two inhalations twice daily plus tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily (2,691 randomised patients).
V študiji TRINITY so primerjali zdravilo Trydonis s tiotropijem 18 mikrogramov praška za inhaliranje, trda kapsula, ena inhalacija enkrat na dan; poleg tega so učinke primerjali s trojno kombinacijo, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola 100/6 mikrogramov, dve inhalaciji dvakrat na dan, plus tiotropij 18 mikrogramov prašek za inhaliranje, trda kapsula, ena inhalacija enkrat na dan (2.691 randomiziranih bolnikov).
No differences were observed when comparing Trydonis and the extemporary triple combination made of a fixed combination of beclometasone dipropionate and formoterol plus tiotropium (difference of 3 mL in pre-dose FEV1 after 52 weeks of treatment).
V primerjavi zdravila Trydonis in trojne kombinacije, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola plus tiotropija, niso opazili razlik (razlika 3 ml v FEV1 pred odmerkom po 52 tednih zdravljenja).
• Disulfiram, a medicine used in the treatment of people with alcoholism (drinking problems) or metronidazole, an antibiotic to treat infection in your body can cause side effects (e.g. feeling sick, being sick, stomach pain) due to the small amount of alcohol in Trydonis.
• disulfiram, zdravilom, ki se uporablja za zdravljenje ljudi z alkoholizmom ali metrodinazolom, antibiotikom za zdravljenje okužb v telesu lahko zaradi majhne količine alkohola v zdravilu
Trydonis 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution
Trydonis 87 mikrogramov/5 mikrogramov/9 mikrogramov inhalacijska raztopina pod tlakom
Compared with tiotropium, Trydonis also reduced the rate of severe exacerbations (i.e. excluding moderate exacerbations) by 32% (rate: 0.067 versus 0.098 events per patient/year; p = 0.017).
V primerjavi s tiotropijem je zdravilo Trydonis zmanjšalo tudi stopnjo hudih poslabšanj (tj. brez zmernih poslabšanj) za 32 % (razmerje: 0,067 v primerjavi z 0,098 dogodka na bolnika/leto; p = 0,017).
• medicines for treating - abnormal heart rhythms (quinidine, disopyramide, procainamide), - allergic reactions (antihistamines), - symptoms of depression or mental disorders such as monoamine oxidase inhibitors (for example phenelzine and isocarboxazid), tricyclic antidepressants (for example amitriptyline and imipramine), phenothiazines can cause some changes in the electrocardiogram (ECG, heart trace).
- alergijskih reakcij (antihistaminiki), - simptomov depresije ali duševnih bolezni, kot so zaviralci monoaminooksidaze (na primer fenelzin in izokarboksazid), triciklični antidepresivi (na primer amitriptilin in imipramin),
Study TRILOGY compared Trydonis with a fixed combination of beclometasone dipropionate and formoterol 100/6 micrograms two inhalations twice daily (1,368 randomised patients).
V študiji TRILOGY so primerjali zdravilo Trydonis s fiksno kombinacijo beklometazondipropionata in formoterola 100/6 mikrogramov, dve inhalaciji dvakrat na dan (1.368 randomiziranih bolnikov).
Contents of the pack and other information
Shranjevanje zdravila Trydonis Vsebina pakiranja in dodatne informacije
Compared with a fixed combination of indacaterol and glycopyrronium, Trydonis improved average pre-dose FEV1 over the 52-week treatment period by 22 mL (p=0.018).
V primerjavi s fiksno kombinacijo indakaterola in glikopironija je zdravilo Trydonis izboljšalo povprečni FEV1 pred odmerkom po 52-tedenskem zdravljenju za 22 ml (p = 0,018).
Trydonis is used as a maintenance treatment for your COPD.
Zdravilo Trydonis se uporablja za vzdrževalno zdravljenje KOPB.
Trydonis comes in a pressurised container (coated aluminium), with a metering valve.
Zdravilo Trydonis je na voljo v tlačnem vsebniku (obloženem z aluminijem) z odmernim ventilom.
No differences were observed when comparing Trydonis with the extemporary triple combination made of beclometasone dipropionate and formoterol fixed combination plus tiotropium (moderate/severe exacerbation rate: 0.46 versus 0.45 events per patient/year).
V primerjavi zdravila Trydonis s trojno kombinacijo, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola plus tiotropija, niso opazili razlik (razmerje zmernih/hudih poslabšanj: 0,46 v primerjavi z 0,45 dogodka na bolnika/leto).
TRIBUTE was a 52-week activecontrolled study comparing Trydonis with a fixed combination of indacaterol/glycopyrronium 85/43 micrograms inhalation powder, hard capsule, one inhalation once daily (1,532 randomised patients).
TRIBUTE je bila 52-tedenska študija, nadzorovana z učinkovino, v kateri so primerjali zdravilo Trydonis s fiksno kombinacijo indakaterola/glikopironija 85/43 mikrogramov prašek za inhaliranje, trda kapsula, ena inhalacija enkrat na dan (1.532 randomiziranih bolnikov).
No differences were observed when comparing Trydonis and the extemporary triple combination made of fluticasone and vilanterol fixed combination plus tiotropium.
V primerjavi zdravila Trydonis in trojne kombinacije, sestavljene iz fiksne kombinacije flutikazona in vilanterola plus tiotropija ni bilo opaznih razlik.
• problems with how your adrenal glands work (adrenal suppression)
• težave z delovanjem nadledvične žleze (adrenosupresija);
The pharmacokinetics of beclometasone dipropionate in patients with hepatic impairment has not been studied, however, as beclometasone dipropionate undergoes a very rapid metabolism via esterase enzymes present in intestinal fluid, serum, lungs and liver to form the more polar products beclometasone 21-monopropionate, beclometasone 17-monopropionate and beclometasone, hepatic impairment is not expected to modify the pharmacokinetics and safety profile of beclometasone dipropionate.
Farmakokinetike beklometazondipropionata pri bolnikih z jetrno okvaro niso preučili, vendar pa se ne pričakuje, da bi jetrna okvara spremenila farmakokinetiko in profil varnosti beklometazondipropionata, saj se beklometazondipropionat zelo hitro presnovi z encimi esteraze, ki so prisotni v črevesnem soku, serumu, pljučih in jetrih, in tvori bolj polarne produkte, beklometazon 21
Talk to your doctor or pharmacist before using Trydonis:
Pred začetkom uporabe zdravila Trydonis se posvetujte z zdravnikom ali farmacevtom:
Compared with tiotropium, Trydonis improved pre-dose FEV1 by 51 mL after 26 weeks of treatment and by 61 mL after 52 weeks of treatment.
V primerjavi s tiotropijem je zdravilo Trydonis izboljšalo FEV1 pred odmerkom za 51 ml po 26-tedenskem zdravljenju in za 61 ml po 52-tedenskem zdravljenju.
• if you experience eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes.
zlasti v predelu oči, obraza, ustnic in žrela; • če opazite bolečino ali težave z očesom, začasno zamegljen vid, očesne kolobarje ali barvne slike, povezane s pordelim očesom.
Immediate hypersensitivity reactions have been reported after administration of Trydonis.
Preobčutljivost Po jemanju zdravila Trydonis so poročali o takojšnjih preobčutljivostnih reakcijah.
Compared with a fixed combination of beclometasone dipropionate and formoterol, Trydonis significantly improved 2-hour post dose FEV1 by 117 mL after 26 weeks of treatment and by 103 mL after 52 weeks of treatment (p < 0.001).
V primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola je zdravilo Trydonis značilno izboljšalo FEV1 2 uri po odmerku za 117 ml po 26-tedenskem zdravljenju in za 103 ml po 52-tedenskem zdravljenju (p < 0,001).
• inflammation of the sinuses
• gripa; • vnetje sinusov;
Beclometasone dipropionate given by inhalation at recommended doses has a glucocorticoid antiinflammatory action within the lungs.
V priporočenih odmerkih inhalirani beklometazondipropionat deluje v pljučih glukokortikoidno protivnetno.
Compared with a fixed combination of indacaterol and glycopyrronium, Trydonis reduced the rate of moderate/severe exacerbations over 52 weeks by 15% (rate: 0.50 versus 0.59 events per patient/year; p = 0.043).
V primerjavi s fiksno kombinacijo indakaterola in glikopironija je zdravilo Trydonis v 52 tednih zmanjšalo stopnjo zmernih/hudih poslabšanj za 15 % (razmerje: 0,50 v primerjavi z 0,59 dogodka na bolnika/leto; p = 0,043).
Compared with a fixed combination of beclometasone dipropionate and formoterol, Trydonis improved pre-dose FEV1 by 81 mL after 26 weeks of treatment and by 63 mL after 52 weeks of treatment.
V primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola je zdravilo Trydonis izboljšalo FEV1 pred odmerkom za 81 ml po 26-tedenskem zdravljenju in za 63 ml po 52-tedenskem zdravljenju.
Trydonis is a pressurised inhalation, solution.
Zdravilo Trydonis je inhalacijska raztopina pod tlakom.
Compared with a fixed combination of beclometasone dipropionate and formoterol, Trydonis reduced the rate of moderate/severe exacerbations over 52 weeks by 23% (rate: 0.41 versus 0.53 events per patient/year; p = 0.005).
V primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola je zdravilo Trydonis v 52 tednih zmanjšalo stopnjo zmernih/hudih poslabšanj za 23 % (razmerje: 0,41 v primerjavi z 0,53 dogodka na bolnika/leto; p = 0,005).
It is important that you take your dose as advised by your doctor.
Če ste uporabili večji odmerek zdravila Trydonis, kot bi smeli Pomembno je, da uporabite odmerek, ki vam ga je svetoval zdravnik.
Trydonis significantly improved dyspnoea (measured as the Transition Dyspnoea Index - TDI - focal score) after 26 weeks of treatment compared with baseline (by 1.71 units; p < 0.001), but the adjusted mean difference versus a fixed combination of beclometasone dipropionate and formoterol was not statistically significant (0.21 units; p = 0.160).
p < 0,001), vendar prilagojena srednja razlika v primerjavi s fiksno kombinacijo beklometazondipropionata in formoterola ni bila statistično značilna (0,21 enot; p = 0,160).
Compared with tiotropium, Trydonis reduced the rate of moderate/severe exacerbations over 52 weeks by 20% (rate: 0.46 versus 0.57 events per patient/year; p = 0.003).
V primerjavi s tiotropijem je zdravilo Trydonis v 52 tednih zmanjšalo stopnjo zmernih/hudih poslabšanj za 20 % (razmerje: 0,46 v primerjavi z 0,57 dogodka na bolnika/leto; p = 0,003).
Use of Trydonis in patients with severe renal impairment or end-stage renal disease requiring dialysis, especially if associated with significant body weight reduction, should be considered only if the expected benefit outweighs the potential risk (see section 4.4 and section 5.2).
ki zahteva dializno zdravljenje, zlasti v povezavi s pomembnim zmanjšanjem telesne mase, je možna le, če so pričakovane koristi večje od možnih tveganj (glejte poglavje 4.4 in poglavje 5.2).
Trydonis should be used with caution in patients with cardiac arrhythmias, especially third degree atrioventricular block and tachyarrhythmias (accelerated and/or irregular heart beat), idiopathic subvalvular aortic stenosis, hypertrophic obstructive cardiomyopathy, severe heart disease (particularly acute myocardial infarction, ischaemic heart disease, congestive heart failure), occlusive vascular diseases (particularly arteriosclerosis), arterial hypertension and aneurysm.
idiopatsko subvalvularno aortno stenozo, hipertrofično obstruktivno kardiomiopatijo, hudo boleznijo srca (zlasti akutni miokardni infarkt, ishemična bolezen srca, kongestivno srčno popuščanje),
The study compared data obtained after treatment with a single dose of Trydonis (4 inhalations of 100/6/25 micrograms, a non-marketed formulation containing twice the approved strength of glycopyrronium) or a single dose of the extemporary combination of beclometasone dipropionate/formoterol (4 inhalations of 100/6 micrograms) plus glycopyrronium (4 inhalations of 25 micrograms).
100/6/25 mikrogramov, s formulacijo, ki je ni na trgu n ki vsebuje dvakratno odobreno jakost glikopironija) ali enkratnim odmerkom trojne kombinacije, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola 100/6 mikrogramov (4 inhalacije po 100/6 mikrogramov)
Trydonis 87/5/9 micrograms pressurised inhalation, solution beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium
Trydonis 87/5/9 mikrogramov inhalacijska raztopina pod tlakom beklometazondipropionat/formoterolijev fumarat dihidrat/glikopironij
TRISTAR was a 26-week active-controlled open label study comparing Trydonis with an extemporary combination made of a fixed combination of fluticasone/vilanterol 92/22 micrograms inhalation powder, one inhalation once daily plus tiotropium 18 micrograms inhalation powder, hard capsule, one inhalation once daily (1,157 randomised patients).
Trydonis s kombinacijo, sestavljeno iz fiksne kombinacije flutikazona/vilanterola 92/22 mikrogramov prašek za inhaliranje, ena inhalacija enkrat na dan plus tiotropij 18 mikrogramov prašek za inhaliranje, trda kapsula, ena inhalacija enkrat na dan (1.157 randomiziranih bolnikov).
• fungal infections of the chest
• glivične okužbe prsnega koša;
Package leaflet: Information for the user Trydonis 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium
Navodilo za uporabo Trydonis 87 mikrogramov/5 mikrogramov/9 mikrogramov inhalacijska raztopina pod tlakom beklometazondipropionat/formoterolijev fumarat dihidrat/glikopironij
If you have been using a different inhaler containing beclometasone dipropionate previously, ask your doctor for advice, as the effective dose of beclometasone dipropionate in Trydonis for the treatment of COPD may be lower than that of some other inhalers.
saj je učinkoviti odmerek beklometazondipropionata v zdravilu Trydonis za zdravljenje KOPB morda manjši kot v nekaterih drugih inhalatorjih.
• flu
• nemir;
In addition, compared with both a fixed combination of beclometasone dipropionate and formoterol and with tiotropium, Trydonis significantly prolonged the time to first exacerbation (hazard ratio 0.80 and 0.84 respectively; p = 0.020 and 0.015 respectively), with no differences between Trydonis and the extemporary triple combination made of beclometasone dipropionate and formoterol fixed combination plus tiotropium (hazard ratio 1.06).
0,84; p = 0,020 oz. 0,015), brez razlik med zdravilom Trydonis in trojno kombinacijo, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola plus tiotropija (razmerje tveganja 1,06).
Trydonis 87/5/9 micrograms pressurised inhalation beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium Inhalation use
Trydonis 87/5/9 mikrogramov inhalacijska raztopina pod tlakom beklometazondipropionat/formoterolijev fumarat dihidrat/glikopironij za inhaliranje
For glycopyrronium, the maximum plasma concentration was similar after administration of the fixed or extemporary combination, while the systemic exposure was slightly higher after administration of Trydonis than with the extemporary combination.
Za glikopironij je bila največja koncentracija v plazmi podobna po dajanju fiksne kombinacije ali trojne kombinacije, ki je bila sestavljena iz fiksne kombinacije beklometazondipropionata in formoterola plus glikopironija,
How to store Trydonis
Shranjevanje zdravila Trydonis
The daily dose of Trydonis corresponds to a medium dose of inhaled corticosteroid; furthermore, these effects are much less likely to occur than with oral corticosteroids.
Ti učinki so bistveno manj verjetni med uporabo inhaliranih kortikosteroidov kot med uporabo peroralnih kortikosteroidov.
• if you have difficulty passing urine.
• če imate težavo z očmi, imenovano glavkom z zaprtim zakotjem; • če imate težave z odvajanjem urina;
The long-term co-administration of Trydonis with other anticholinergic-containing medicinal products has not been studied and is therefore not recommended (see section 4.4).
niso preučili in se zato ne priporoča (glejte poglavje 4.4).
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS ALUMINIUM CONTAINER
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
The combination of Trydonis with some other COPD medicines or medicines such as diuretics (medicines that make the body lose water, to treat heart disease or high blood pressure), can cause a sharp fall in your blood level of potassium.
Kombinacija zdravila Trydonis z nekaterimi drugimi zdravili za KOPB ali zdravili, kot so npr. diuretiki (zdravili za odvajanje vode,
Therefore, your doctor may wish to measure the potassium levels in your blood from time to time.
Zato vam bo zdravnik morda občasno spremljal koncentracijo kalija v krvi; • če imate katero od bolezni jeter ali ledvic;
• fungal infections of the throat or of the food pipe (oesophagus)
• glivične okužbe žrela ali požiralnika;
• trembling
Trydonis.
The exact way in which levetiracetam works is still unclear but it seems to interfere with a protein called synaptic vesicle protein 2A, which is found in the spaces between nerves and is involved in the release of chemical messengers from nerve cells.
Natančen način delovanja levetiracetama še vedno ni pojasnjen, toda zdi se, da vpliva na beljakovino, imenovano sinaptični vezikularni protein 2A, ki se nahaja v prostoru med živčnimi celicami in zavira sproščanje kemičnih prenašalcev iz živčnih celic.
The European Commission granted a marketing authorisation valid throughout the European Union for Matever on 03 October 2011.
Evropska komisija je dovoljenje za promet z zdravilom Matever, veljavno po vsej Evropski uniji, odobrila dne 03. oktobra 2011.
This is a type of epilepsy where too much electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one part of the body, distorted hearing, sense of smell or vision, numbness, or a sudden sense of fear.
To je vrsta epilepsije, pri kateri prevelika električna aktivnost na samo eni strani možganov povzroči simptome, kot so nenadni sunkoviti gibi enega dela telesa, motnje sluha, voha ali vida, odrevenelost ali nenaden občutek strahu.
What are the benefits and risks of Matever?
Kakšne so koristi in tveganja, povezani z zdravilom Matever?
The full EPAR for Matever can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Matever je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
For more information about treatment with Matever, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Matever preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
It is available as tablets (250 mg, 500 mg, 750 mg and 1000 mg) and as a concentrate that is made up into a solution for infusion (drip into a vein, 100 mg/ml).
Na voljo je v obliki tablet (250 mg, 500 mg, 750 mg in 1 000 mg) in v obliki koncentrata za pripravo raztopine za infundiranje (kapalne infuzije v veno, 100 mg/ml).
This means that Matever is similar to a ‘reference medicine' already authorised in the European Union (EU) called Keppra.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Keppra.
Lower doses are used in patients who have problems with their kidneys (such as older patients).
Manjši odmerki se uporabljajo pri bolnikih, ki imajo težave z delovanjem ledvic (na primer starejši bolniki).
This is a summary of the European public assessment report (EPAR) for Matever.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Matever.
This helps Matever to stabilise electrical activity in the brain and prevent seizures.
To omogoča zdravilu Matever, da stabilizira električno aktivnost v možganih in prepreči napade.
• primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
• primarno generaliziranih tonično-kloničnih napadov (daljših napadov, vključno z izgubo zavesti) pri bolnikih od 12. leta starosti dalje z idiopatsko generalizirano epilepsijo (vrsto epilepsije, za katero se domneva, da je genetskega izvora).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Matever.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Matever, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Matever tablets are swallowed with liquid.
Tablete Matever je treba pogoltniti s tekočino.
Because Matever is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Matever generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
The Committee recommended that Matever be given marketing authorisation.
Odbor je zato priporočil, da se za zdravilo Matever odobri dovoljenje za promet.
Matever can also be used as an add-on to other anti-epileptic medicines to treat:
Zdravilo Matever se lahko uporablja kot dopolnilno zdravljenje k drugim zdravilom proti epilepsiji za zdravljenje:
The active substance in Matever, levetiracetam, is an anti-epileptic medicine.
Zdravilna učinkovina v zdravilu Matever, levetiracetam, je zdravilo proti epilepsiji.
Other information about Matever
Druge informacije o zdravilu Matever:
The daily dose can be increased up to 1500 mg twice a day.
Dnevni odmerek se lahko poveča do največ 1 500 mg dvakrat na dan.
In patients aged between six months and 17 years weighing less than 50 kg, the starting dose is 10 mg per kilogram body weight twice a day, which can be increased up to 30 mg/kg twice a day.
Pri otrocih od šestega meseca do 17. leta starosti, ki tehtajo manj kot 50 kg, je začetni odmerek 10 mg/kg telesne mase dvakrat dnevno, ki ga je mogoče povečati vse do 30 mg/kg telesne mase dvakrat dnevno.
Why has Matever been approved?
Zakaj je bilo zdravilo Matever odobreno?
Because Matever is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Keppra.
Ker je zdravilo Matever generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Keppra.
Matever can be given as an infusion using the same doses at the same frequency when using the tablets or the oral solution is not possible.
Zdravilo Matever se lahko daje kot infuzija v enakih odmerkih in enako pogosto, kadar uporaba tablet ali peroralne raztopine ni mogoča.
Matever is a medicine that contains the active substance levetiracetam.
Matever je zdravilo, ki vsebuje zdravilno učinkovino levetiracetam.